Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA seq analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

ABSTRACT: Transcriptome analysis of lineage-marked prostate primary tumors and metastases from the NPK mouse model (Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+)

ORGANISM(S): Mus musculus

PROVIDER: GSE143812 | GEO | 2020/08/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Whole-exome sequencing analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

Project description:Whole-exome sequencing analysis of lineage-marked prostate primary tumors and metastases from the NPK mouse model (Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+)

2020-08-11 | GSE143814 | GEO

Single-cell RNA seq analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

Project description:Single-cell transcriptome analysis of lineage-marked prostate primary tumors and metastases from the NPK mouse model (Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+)

2020-08-11 | GSE143813 | GEO

Primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

Project description:Primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

| PRJNA601760 | ENA

RNA seq analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

Project description:RNA seq analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

| PRJNA601755 | ENA

Whole-exome sequencing analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

Project description:Whole-exome sequencing analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

| PRJNA601758 | ENA

Single-cell RNA seq analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

Project description:Single-cell RNA seq analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+ Ptenflox/flox KrasLSL-G12D/+ R26R-CAG-LSL-EYFP/+) prostate cancer mouse model

| PRJNA601759 | ENA

Targeting NSD2 in mouse prostate cancer cells

Project description:Transcriptome analysis of mouse prostate cancer cell line (NPK) silenced for Nsd2 using shRNA or treated with MCTP--39. NPK prostatre cancer cells are derived Nkx3.1CreERT2/+ ;Ptenflox/flox;KrasLSL-G12D/+ mice, and were used to silence the histone methyltransferase NSD2 or treat them with the NSD2 inhibitor MCTP39 for subsequent gene expression profiling by RNAseq

2019-07-23 | GSE118784 | GEO

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (II)

Project description:Analysis of the transcriptome of allografted mouse tumors after treatment with rapamycin and PD0325901. Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+ (NPK mice) were induced and their tumors removed to generate allograft lines by implanting a 1.5 mm3 tumor fragment in the subcutaneous space of athymic nude mice. Allografted NPK tumors were allowed to grow until they reached a volume of 1 cm3, at which moment they were randomly assigned to either vehicle (Veh) or combination therapy using rapamycin and PD0325901 (RAPPD). Allografted mice were administered rapamycin (10 mg/kg) and PD0325901 (10 mg/kg) during five consecutive days (Allo SHORT). Mice were euthanized in the fifth day 6 hours after having received the last treatment and the tumors were harvested and snap frozen for subsequent molecular analysis.

2015-09-17 | GSE69213 | GEO

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (II)

2015-09-17 | E-GEOD-69213 | biostudies-arrayexpress

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (I)

Project description:Analysis of the transcriptome of mouse models of prostate cancer after treatment with rapamycin and PD0325901 combination therapy or standard of care docetaxel. The Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+ (NPK mice) was used in this study. Two months after tumor induction, mice were randomly assigned to vehicle (Veh) or treatments groups, such as rapamycin and PD0325901 (RAPPD) or docetaxel (Docetaxel). For the treatment groups mice were administered rapamycin (10 mg/kg) and PD0325901 (10 mg/kg) or docetaxel (10 mg/kg) for 5 days (SHORT) or for 1 month (LONG). At the end of the treatment, mice were euthanized, tumors harvested and snap frozen for subsequent molecular analysis.

2015-09-17 | GSE69211 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data